Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection
about
Antiretroviral therapy response among HIV-2 infected patients: a systematic reviewCyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaborationPotent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.HIV-2 genomic RNA accumulates in stress granules in the absence of active translation.Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsUpdate on human immunodeficiency virus (HIV)-2 infection.Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes.Human immunodeficiency virus type 2 in two Saudi families.Rapid evolution of the env gene leader sequence in cats naturally infected with feline immunodeficiency virus.Human Immunodeficiency Virus Type 2 (HIV-2) Gag Is Trafficked in an AP-3 and AP-5 Dependent Manner.Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strainsFrequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine DevelopmentH11/HSPB8 Restricts HIV-2 Vpx to Restore the Anti-Viral Activity of SAMHD1.Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.Conservation of Nef function across highly diverse lineages of SIVsmm.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.A 5'UTR-spliced mRNA isoform is specialized for enhanced HIV-2 gag translation.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.Mortality and survival patterns of people living with HIV-2Novel inhibitors of human immunodeficiency virus type 2 infectivity.HIV-2 A-subtype gp125c₂-v₃-c₃ mutations and their association with CCR5 and CXCR4 tropism.Different effects of the TAR structure on HIV-1 and HIV-2 genomic RNA translation.Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010.Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses.Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.High level of HIV-2 false positivity in KwaZulu-Natal province: a region of South Africa with a very high HIV-1 subtype C prevalence.Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.Differences in proviral DNA load between HIV-1-infected and HIV-2-infected patients.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
P2860
Q27003854-2579C0DA-F7DD-4109-960A-9DE0BC874A39Q30400372-C6C0355E-4981-463D-9EFB-6A899043E82AQ33809419-1690BEEB-F8D9-400E-880B-963B28187374Q33891896-EBB5267E-8096-4B44-A37B-01B8B7C7F5A8Q34290973-5E88BC97-21B6-4F73-8CB1-099288BD4E14Q34387349-EA713934-463B-48F0-9C92-144C6A9122EAQ34489574-19A007B0-EF52-4A77-9CA2-1E4A05EE58E4Q34742090-8AE4CC47-B4A3-4819-A1F1-33F682C90773Q35019924-ED87D4AC-B23E-4864-A912-0F1B93751B67Q35115656-D874F882-8873-49C6-85D1-00A1980D2B31Q35165841-72F75965-649F-4C3F-A083-379B54887410Q35182754-67F13494-90D6-497B-9E0E-908BE024360BQ36071753-CB7BA3F7-A28A-49F0-8B86-ECB8C7CBD058Q36358780-EA906595-B8FE-4D73-9D83-9CD414705B4AQ36634790-119D657C-006D-4C8D-927C-E9B79A196E5AQ36651031-F16DF459-B737-499F-88A1-8A0F4860B448Q36996391-97263BA0-A682-4E3E-B38E-0F0971061B5BQ37130458-E93A7F72-83E7-4327-BF7E-3FC89FF00B08Q37182075-E1F0E84B-B09A-4FF2-9332-FF5684AA3990Q37256366-BEA335A0-D891-4036-BAAA-BEC5017ACD8BQ37307096-71B6565A-9287-4C45-B117-8B082F2BDA5CQ37361258-794C448C-25AF-403A-9239-F7DC3F7B939BQ38717198-FE915B7E-3C7D-4822-9E5D-EC051A386318Q38752077-12E4B976-2EA9-4900-BF2C-A1480627BE4AQ38851677-0550F8E5-1F49-4EFB-BAD4-C5A808D31836Q38967949-CB221190-2972-4A71-AF3F-01D0863BB9E7Q38973555-212232B5-9F72-46A4-A1D3-56BE109BFDEFQ39436460-04123CE5-A9CE-4FFC-A5D7-5079522566F3Q39497261-3DA736D6-C03F-4A90-823C-5C9B73524D65Q40069610-62368B63-B93D-4B4D-A49C-24A068C64B40Q40432241-FD3A6146-F7C4-4783-B87A-0CEE8E6B06F9Q40485909-C2D0BDC7-9ACF-41E2-BA2D-DBA95776816DQ41548052-E8A81E22-C6F1-490B-8D7D-9DB92C5D15CAQ42264071-3A918F27-D24D-4483-9D9B-AE68BDC77B51Q42275624-6ABCC004-69FA-4E44-8AE5-4BF90C2D4F0AQ42318282-88EBDAAE-A1ED-46A8-A5FD-71447A1A78EAQ43143940-4A12F842-0036-4759-A335-3DF1AABCCDEFQ43170527-724B1A76-6B4F-4A7D-BF3F-43297D4C17F5Q44990505-8E614092-D11B-48F6-92D4-8445EE1B4800Q52625498-894E0EE3-EF2B-43E0-865A-42934705F090
P2860
Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Direct evidence of lower viral ...... ection than in HIV-1 infection
@ast
Direct evidence of lower viral ...... ection than in HIV-1 infection
@en
type
label
Direct evidence of lower viral ...... ection than in HIV-1 infection
@ast
Direct evidence of lower viral ...... ection than in HIV-1 infection
@en
prefLabel
Direct evidence of lower viral ...... ection than in HIV-1 infection
@ast
Direct evidence of lower viral ...... ection than in HIV-1 infection
@en
P2093
P2860
P356
P1433
P1476
Direct evidence of lower viral ...... ection than in HIV-1 infection
@en
P2093
Abdoulaye Dieng Sarr
Adam MacNeil
Jean-Louis Sankalé
Phyllis Kanki
Seema Thakore Meloni
P2860
P304
P356
10.1128/JVI.02625-06
P407
P577
2007-02-28T00:00:00Z